Codexis AI Stock Analysis
Codexis (4QK) AI Stock Analysis
Codexis
(Frankfurt:4QK)
No summary available
Codexis (4QK) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 116.17M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,533
- Price to Earnings (P/E)
- -5.4
- Beta (1Y)
- 0.93
- Revenue Growth
- 57.86%
- EPS Growth
- 75.05%
- Country
- Germany
- Employees
- 146
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Codexis Business Overview & Revenue Model
Company Description
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemi...
Codexis Earnings Call Summary
The call was strongly positive overall. Highlights included substantial revenue growth, improving gross margins, lower operating expenses, improved biocatalysis product sales, progress to 100-gram ECO Synthesis scale, three to fourfold higher potency in stereocontrolled siRNA, growing customer and CDMO engagement, and a cash runway expected through 2028. The main negatives were the continuing net loss, a lower cash balance versus year-end 2025, the remaining work required to reach larger-scale manufacturing, and uncertain timing for additional commercial agreements.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Codexis reiterated its 2026 top line guidance, expecting revenue in the range of $72 million to $76 million, and now anticipates achieving gross margins in the low 70s for the full year 2026; the company expects that its current cash will be sufficient to fund planned operations and capital expenditures through 2028, in line with previous cash runway guidance, and said it will be moving toward 500-gram production scale, advancing the ECO Synthesis raw material supply chain, and beginning construction on its GMP production facility.
Codexis Risk Analysis
Codexis disclosed 50 risk factors in its most recent earnings report. Codexis reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
2 New RisksCodexis Peers Comparison
Overall Rating
CGEN66Neutral
DTIL54Neutral
MXCT50Neutral
CBUS45Neutral
ADAG41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 66Neutral | $193.24M | 5.26 | 39.30% | ― | 999.97% | ― | |
| 54Neutral | $203.37M | -5.97 | -58.09% | ― | 6353.01% | 84.80% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $121.84M | -4.52 | -17.24% | ― | -0.13% | 38.72% | |
| 45Neutral | $91.71M | -0.78 | -581.53% | ― | 19.45% | 53.78% | |
| 41Neutral | $107.43M | -3.14 | -29.09% | ― | 8906.15% | 41.48% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:4QK | Codexis | 0.94 | -0.45 | -32.18% | |
| CGEN | Compugen | 2.02 | 0.42 | 26.25% | |
| MXCT | MaxCyte, Inc. | 1.17 | -0.53 | -31.18% | |
| CBUS | Cibus, Inc. | 1.39 | 0.12 | 9.45% | |
| DTIL | Precision Biosciences | 7.05 | 2.23 | 46.27% | |
| ADAG | Adagene, Inc. | 1.48 | -0.33 | -18.23% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
